Brief: Mirum Pharmaceuticals Completes Enrollment In Phase 3 Expand Study Of Livmarli® (Maralixibat) In Additional Rare Cholestatic Liver Diseases
16/03/2026 12:10
March 16 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 EXPAND STUDY OF LIVMARLI® (MARALIXIBAT) IN ADDITIONAL RARE CHOLESTATIC LIVER DISEASES MIRUM PHARMACEUTICALS INC - TOPLINE DATA FROM EXPAND STUDY EXPECTED IN Q4 2026 Source text: ID:nBw8yQPnPa Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX